NICE Clinical Guideline 89

When to suspect child maltreatment

The recommendations from NICE cover:
  • Physical features including:
    • bruises
    • lacerations (cuts), abrasions, and scars
    • intracranial injuries
  • Neglect—failure of provision and/or supervision
  • Emotional, behavioural, interpersonal, and social functioning
  • Sexual abuse
  • Parent/carer–child interactions.
 
Web address: www.nice.org.uk/Guidance/CG89

NICE Technology Appraisal 173

Tenofovir disoproxil for the treatment of chronic hepatitis

Summary:
  • Tenofovir disoproxil, within its marketing authorisation, is recommended as a treatment option for people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated
  • This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D, or HIV.
 
Web address: www.nice.org.uk/Guidance/TA173

NICE Technology Appraisal 174

Rituximab for the first-line treatment of chronic lymphocytic leukaemia

Summary:
  • Rituximab is recommended as a possible first-line treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide
  • Rituximab should only be used in combination with fludarabine and cyclophosphamide
  • Rituximab is not recommended in combination with any other chemotherapy agents as a first-line treatment for chronic lymphocytic leukaemia.
 
Web address: www.nice.org.uk/Guidance/TA174